Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NAD Refers Star Herbs Blood Pressure Claims To FTC

This article was originally published in The Tan Sheet

Executive Summary

The industry self-regulation group refers My Low Press supplement claims after Star Herbs fails to offer evidence to support its advertising. Referring uncooperative firms to FTC “was one of the things that we found attractive when we created our program with the NAD,” said CRN President and CEO Steve Mister.

You may also be interested in...



Summers Blasts NAD “Secret Rules” After J&J Ointment Claim Challenge

Claims for Summers Labs’ Triple Paste diaper rash ointment spurred Desitin maker Johnson & Johnson to bring a challenge through the National Advertising Division. Summers disagreed with NAD’s conclusion on a physician survey it conducted and declined to discontinue a doctor-recommended claim.

FTC Settlement Looks To Ground Airborne Claims

Under a settlement with the Federal Trade Commission announced Aug. 14, the maker of Airborne dietary supplement products must cease unsubstantiated health-related claims and contribute up to $6.5 million to an existing consumer redress fund

CRN Grants $500K To NAD For Increased Dietary Supplement Monitoring

CRN is committing nearly half a million dollars over a three year period to triple the annual number of dietary supplement cases reviewed by the Council of Better Business Bureaus' National Advertising Division (NAD)

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel